A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) - Trial NCT06122649
Access comprehensive clinical trial information for NCT06122649 through Pure Global AI's free database. This Phase 3 trial is sponsored by Amgen and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Amgen
Timeline & Enrollment
Phase 3
Nov 27, 2023
Dec 24, 2025
Primary Outcome
Number of Participants Achieving at least a 75% Reduction (Improvement) From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16
Summary
The study aims to evaluate the clinical efficacy of oral apremilast 30 mg BID compared with
 placebo in Chinese participants with moderate to severe PsO
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06122649
Non-Device Trial